Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOLT-203 in Primary Hyperoxaluria Type 1
NCT07587021Phase 2Recruiting
- Sponsor
- YolTech Therapeutics
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary Hyperoxaluria Type 1 (PH1) comparing YOLT-203 First with Placebo First (2 arms). Primary endpoint: Percent Change From Baseline in 24-Hour Urinary Oxalate (BSA-Corrected). Started Sep 2026; status: recruiting.
02
Drugs
YOLT-203
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on NCT07587021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587021.